Impact of early nutrition on brain development and neurocognitive outcomes in very preterm infants

Impact of early nutrition on brain development and neurocognitive outcomes in very preterm infants

Background

A highly important long-term health outcome of early life experiences in infants born preterm is neurodevelopment which, to a large extent, is pre-programmed and thus experience-independent. There are however several important and at least partly modifiable environmental factors that might impact brain growth and differentiation, such as infection/inflammation, oxidative stress, environmental enrichment, and nutrition. Of these, the latter is directed almost entirely by medical caregivers and can from a simplistic view either optimally support neurodevelopment with normal fetal growth serving as the reference or be left ignored and confer an additional risk of central nervous system harm. The late stages of gestation are critical for brain growth and development, and preterm neonates are particularly vulnerable to disruptions in this process since a larger proportion of their neurogenesis and maturation occur outside the womb.1

Despite efforts to enrich enteral feeds and, to optimize supportive parenteral nutrition, it has been demonstrated that preterm infants later have smaller brain volumes than term-born infants, and this is paralleled by impairment of neurocognitive development.2 Infants born extremely preterm, those with a gestational age of less than 28 weeks, are at the highest risk of postnatal malnutrition due to enteral feeding intolerance, deficient enteral uptake, and limited nutrient reserves.3 While studies in developmental neuropathology emphasize the important role of nutrition in shaping brain structure, the specific impact of macronutrients on brain volume remains unclear.4,5,6,7

The present study aimed to investigate the impact of nutritional provision on brain development in preterm infants, based on the hypothesis that the amount, route and/or composition of nutrients provided during the first weeks may influence brain volumes and later cognition.

Methods

Subjects

All very preterm (VPT, n = 170) infants with a gestational age (GA) of less than 32 weeks cared for at Uppsala University Children’s Hospital from July 2011 to December 2014 were considered eligible for participation (Fig. 1). Among the 170 infants, 150 survived and 118 had brain magnetic resonance imaging (MRI) performed at term as part of the clinical routine. Informed parental consent for study inclusion was obtained for 87 infants and after exclusion of 15 outborn infants, for whom full nutritional data could not be retrieved, 72 infants remained to constitute the final study cohort (Fig. 1).

Fig. 1
Impact of early nutrition on brain development and neurocognitive outcomes in very preterm infants

STROBE flowchart of the study cohort.

Full size image

Perinatal characteristics

Data collected included gestational age (GA) (in days, estimated using routine second trimester ultrasound), antenatal steroid exposure and timing of administration, mode of delivery, birth weight (z-score), Apgar scores, and sex (Table 1). The number of days on mechanical ventilation was used as a proxy for illness severity. Bronchopulmonary dysplasia (BPD) was defined as the receipt of supplemental oxygen at 36 weeks postmenstrual age (PMA).8 Sepsis was defined by clinical symptoms and either a positive blood culture or clearly (>25 mg/dL) elevated C-reactive protein. Necrotizing enterocolitis (NEC) was defined as a histopathological diagnosis after laparotomy. Persistent ductus arteriosus (PDA) treatment included surgical ligation or catheter-based closure. Retinopathy of prematurity (ROP) was classified and staged according to The International Classification of Retinopathy of Prematurity9 with treatment being either laser photocoagulation or intravitreal injection of anti-VEGF.10

Table 1 Clinical characteristics and neurodevelopmental assessment of study cohort.
Full size table

Nutrition data

All nutrients provided were retrieved from electronic medical records and nutrition charts and entered into the macro- and micronutrient calculation software Nutrium™ (Nutrium AB, Umeå, Sweden), to determine the cumulative intake per kilogram body weight of fluid, calories and macronutrients (protein, carbohydrate, lipid) for the first seven, and 28 days. Changes in body weight were calculated as z-scores and percentages.

The institutional nutritional protocol used during the study period was based on current ESPGHAN recommendations.11 In brief, a volume-based protocol, adjusted for weight and adapted to GA was used with a starting total fluid intake ranging from 120 (at 22 weeks GA) to 80 (at 27 weeks GA) mL/kg/day, subsequently adjusted to limit a maximal initial weight loss to 10–15%, and to regain birth weight by 7–14 days. All very preterm infants received either mother’s own milk or donor breast milk, with feeds started within 2 h after birth and continuing every two hours, and with the remaining nutritional needs met by parenteral nutrition. Daily increments of enteral feeds were 20–40 mL/kg/d to a target of 150–170 mL/kg/day within 1-2 weeks depending on gestational age at birth and enteral tolerance.

According to our institutional protocol all infants exclusively receive human (mother’s own, or donor) milk, and fortification is initiated at a postnatal age of four days, or after removal of the umbilical artery catheter in which a sodium-free isotonic amino-acid solution is infused at a rate of 0.5 mL/h in order to keep the line open. The target protein content is 2.4 g/100 mL until a PMA of 28 weeks is reached (4 g/kg/d at 170 ml/kg/d; protein-to-energy ratio ~3.2 g/100 kcal), and 2.1 g/100 mL thereafter (3.5 g/kg/d at 170 ml/kg/d; protein-to-energy ratio ~3.0 g/100 kcal), using PreNAN FM 85 (Nestlé AB, Helsingborg, Sweden). Breast milk is analyzed every two weeks by the Children’s Hospital Nutrition Unit, using 10 ml samples in a breast milk analyzer (Miris, Uppsala, Sweden) after pooling of maternal milk collected over 24 h. Similarly, each batch of donor milk is tested and fortified accordingly.

Brain MRI analysis

The MRIs were performed at term PMA 40.0 ± 1.7 (SD) weeks using 1.5 T scanner (Siemens Avanto, Germany) and an imaging protocol including T2-weighted Fast Spin Echo, T2*-weighted Gradient Echo, Volumetric T1-weighted, and Diffusion-Weighted Imaging (DWI; Single-shot EPI sequences, b-value = 0 and 800 s/mm²). Apparent diffusion coefficients (ADC) were, as previously described,12,13 derived from the DWI data measured in the left periventricular white matter, left basal ganglia, and the pons, by outlining circle-shaped regions-of-interest with predefined radii (Supplementary Fig. S1). The assessments were made by two assessors (N.N. and N.C-M.), blinded to the individual infants’ clinical characteristics and outcomes. While a formal intraclass correlation coefficient analysis was not performed, any discrepancies between the assessors were evaluated by comparing them with the original neuroradiologist’s report to ensure accuracy. Anatomical assessments of both supra- and infratentorial brain structures included intraventricular hemorrhage (IVH) graded according to Papile,14 white matter lesions, ventricular dilatation, basal ganglia injury, and cerebellar hemorrhage. MRIs were also scored according to Kidokoro.15

Brain volume analysis utilized a semi-automated segmentation technique known as Morphologically Adaptive Neonatal Tissue Segmentation (MANTiS) to estimate total brain volume, white matter volume, cortical gray matter volume and cerebellar volume (Supplementary Fig. S2).16,17

Neurodevelopmental assessment

Infants were assessed according to a standardized follow-up program including motor and cognitive assessment at pre-specified ages. Formal testing was made by a child psychologist using the Bayley Scales of Infant and Toddler Development, 3rd edition18 (BSID III), at 2 years of age. A score below 85 in at least one BSID domain (cognitive, language, motor) and/or a diagnosis of cerebral palsy was categorized as neurodevelopmental impairment (NDI).

Statistical analysis

Descriptive parametric and non-parametric tests were utilized for comparisons (mean, standard deviation, median, range), as applicable. Analyses was conducted for the entire group and then separately for two subgroups, extremely preterm (EPT, GA < 28 weeks) and VPT (GA 28-31 weeks), and further stratified by sex. Statistical significance was determined using Fisher’s exact test or the Mann–Whitney U test. Bivariate Pearson and Spearman correlation (depending on the distribution of data) and regressions were used to evaluate the associations between the exposures a) cumulative nutrition provided (Table 2), and b) hospital morbidities, and the outcome variables a) MRI-analyses, and b) neurodevelopment at 2 years.

Table 2 Weight change, feeding progression, and nutritional intakes.
Full size table

The associations between nutrition data and MRI assessments were analyzed using multivariable and logistic regression models, as applicable, and were adjusted for gestational age, days on mechanical ventilation, and postmenstrual age at the time of the MRI examination. Since tests of collinearity demonstrated that gestational age and birth weight had notably similar associations, birth weight z-scores were chosen alongside the other covariates in the analysis. Similarly, the association between nutrient intakes and BSID III scores were analyzed in a multivariable regression analysis adjusted for the above covariates (except age at MRI). The same covariates were included in the evaluation of the correlation between NDI and nutrition data, using a binary logistic regression analysis. Data were analyzed using SPSS Statistical software (Version 29 for Windows, SPSS Inc. Chicago, IL) with p-values < 0.05 considered statistically significant.

Results

The demographic and clinical characteristics of the cohort are presented in Table 1. No infant received postnatal corticosteroids, or insulin.

Nutrition

Table 2 displays the proportion of enteral intake as well as the cumulative total parenteral and enteral intakes during the first four weeks after birth. Mean daily fluid intake and 28 days cumulative caloric intake were higher in the VPT than in the EPT group, with statistical significance determined using a Mann–Whitney U test (p < 0.001).

MRI

The MRI assessments are presented in Table 3. No significant differences in brain volumes, or Kidokoro scores (data not shown), were observed between the EPT and VPT subgroups.

Table 3 Brain MRI morphology, volumetry and diffusion‐weighted imaging.
Full size table

Neurodevelopmental assessment

Follow-up data at 2 years corrected age were available for 59/72 (82%) infants, 49/72 (68%) had BSID III scores, while 10/72 (14%) had been assessed by a psychologist through child habilitation services (Table 1). Eleven infants were categorized as having NDI, and although they mainly belonged to the EPT group the difference between the subgroups was not statistically significant.

Associations between perinatal data, nutrition, MRI, and neurodevelopment

For the whole cohort the bivariate correlation (Spearman) yielded significant positive associations between white matter volume and 28 days cumulative fluid-intake (p = 0.002, r = 0.440), fat (p = 0.002, r = 0.405), carbohydrates (p = 0.001, r = 0.429), protein (p = 0.001, r = 0.425), and calories (p = 0.004, r = 0.421). White matter ADC in the VPT subgroup correlated (Spearman) with enteral fluid intake (p = 0.002, r = 0.610), fat (p < 0.001, r = 0.647), carbohydrates (p = 0.005, r = 0.562), protein (p = 0.003, r = 0.585), and calories (p = 0.002, r = 0.611). However, none of these correlations remained significant after adjusting for covariates in the multivariable regression (Table 4).

Table 4 Multivariable linear regression of 28 days nutritional intakes versus brain volumes, apparent diffusion coefficients, and neurodevelopment.
Full size table

Similarly, for the whole population the BSID-III language index correlated (Spearman) significantly with mean daily fluid intake (p = 0.002, r = 0.540), 28 days cumulative intake of calories (p = 0.007, r = 0.486) and carbohydrate (p < 0.001, r = 0.667), but only prior to covariate-adjustment (Table 4).

Additional regression analyses did not reveal any associations between nutrient intakes (or growth), and brain volumes (Supplementary Table S1), brain morphology (Supplementary Table S2), and neurodevelopment (Supplementary Table S3).

Discussion

We investigated the impact of postnatal nutrition during the first four weeks on neurodevelopment, as evaluated by brain MRI at term and cognitive outcomes at 2 years, in a cohort of very preterm infants. We found no significant correlations between the intakes of the different macronutrients and growth, brain volumes, brain morphology, or cognition in a cohort where all macronutrient intakes were met according to current recommendations.

Our findings are in contrast to those of several previous studies that have reported a positive association between fat intake during the first two weeks of life and brain volumes at term,19,20 or between protein intake during the first four weeks and brain volumes at 30 weeks PMA.21 In the latter study this association was not sustained at term. A notable difference between these studies and the present is that the infants in those cohorts in general received a lower nutritional intake compared to those in our study cohort.

In support of our data Power et al.3 and Hansen-Pupp et al.22 found no association between protein and caloric intakes and brain volumes at term-equivalent age, in cohorts similar to ours regarding both gestational age and nutritional intakes.

Most interestingly, Tan et al.23 reported that an energy intake below 120 kcal/kg/day and a protein intake below 3 g/kg/d during the neonatal period was significantly associated with poorer neurodevelopment. Compared to our data their cohort on average received a lower caloric intake. Two other studies found that total protein intake during the first two and four weeks after birth, respectively, was the single nutritional factor positively correlated with cognitive scores (BSID-III) at 2 years.1,24 On the basis of these conflicting data, several authors have concluded that there is at present no consistent proof of early nutrition influencing neurodevelopmental outcomes.3,25

The challenges in all these studies are the obvious medical complexities of prematurity and the logistical challenges in providing optimal nutrition.26 Infants receiving “better” nutrition (higher cumulative intakes AND a greater proportion of enteral feeds) early after birth are typically healthier, more mature, and require less invasive interventions. Another consideration is that similar intakes may have varying impact on neurocognitive outcomes depending not only on the infant’s gestational age but also on when it occurs during the neonatal period.27 In spite of efforts to adjust for such confounding factors, it is still conceivable that these significantly influence the evaluated outcomes. Thus, it might require both a more homogenous preterm population and a much wider range of nutritional intakes to detect any effect.

The limitations of this study include the relatively small sample and its retrospective design, although we strongly believe our meticulous collection of nutritional data to be adequate. Furthermore, the targeted fortification approach may have contributed to the homogeneous nutritional intake within the cohort, potentially limiting the variability needed to detect any “dose-response effect” between nutrient intakes, and the outcomes evaluated. Other limitations include factors not accounted for in our analyses, such as infant medical condition, and the nutrition provided after the neonatal period, and beyond. The nutrition provided post-discharge, or any complicating illness indeed might individually influence growth and development, and blunt follow-up differences.

In conclusion, the results of this retrospective cohort study reveal no consistent associations between early postnatal nutritional intake in preterm infants and brain volumes at term or neurocognitive outcomes at 2 years. Given the population’s homogeneity in nutritional provision, we cannot preclude that larger deficits in nutritional intakes during the first month of life might have relevant negative effects on brain growth and later cognition.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances

In the context of global ageing, the prevalence of neurodegenerative diseases and dementia, such as Alzheimer’s disease (AD), is increasing. However, the current symptomatic and disease-modifying therapies have achieved limited benefits for neurodegenerative diseases in clinical settings. Halting the progress of neurodegeneration and cognitive decline or even improving impaired cognition and function are the clinically meaningful goals of treatments for neurodegenerative diseases. Ageing is the primary risk factor for neurodegenerative diseases and their associated comorbidities, such as vascular pathologies, in elderly individuals. Thus, we aim to elucidate the role of ageing in neurodegenerative diseases from the perspective of a complex system, in which the brain is the core and peripheral organs and tissues form a holistic network to support brain functions. During ageing, the progressive deterioration of the structure and function of the entire body hampers its active and adaptive responses to various stimuli, thereby rendering individuals more vulnerable to neurodegenerative diseases. Consequently, we propose that the prevention and treatment of neurodegenerative diseases should be grounded in holistic antiageing and rejuvenation means complemented by interventions targeting disease-specific pathogenic events. This integrated approach is a promising strategy to effectively prevent, pause or slow down the progression of neurodegenerative diseases.

Responses

Your email address will not be published. Required fields are marked *